Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Suven Life Sciences Gains 7%; BSE HEALTHCARE Index Up 0.2%
Wed, 30 Oct 12:58

Suven Life Sciences Gains 7%; BSE HEALTHCARE Index Up 0.2%Image source: ipopba/www.istockphoto.com

Suven Life Sciences share price has zoomed 7% and is presently trading at Rs 125.8.

Meanwhile, the BSE HEALTHCARE index is at 43,277.9 (up 0.2%).

Among the top gainers in the BSE HEALTHCARE index today are POLY MEDICURE (up 6.9%) and Natco Pharma (up 3.5%).

Cipla (down 3.6%) and Torrent Pharma (down 2.3%) are among the top losers today.

Over the last one year, Suven Life Sciences has moved up from Rs 75.6 to Rs 125.8, registering a gain of Rs 50.2 (up 66.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,385.2 to 43,277.9, registering a gain of 58.0% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 189.8%), SUVEN PHARMACEUTICALS (up 125.0%) and Glenmark Pharma (up 124.8%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,279.6 (down 0.1%).

The top losers among the BSE Sensex today are ICICI Bank (down 1.7%) and Infosys (down 1.3%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.

In the meantime, NSE Nifty is at 24,449.9 (down 0.1%). Cipla and Dr. Reddys are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,112.7 to 80,279.6, registering a gain of 16,166.9 points (up 25.2%).

Suven Life Sciences Financial Update...

Suven Life Sciences net profit fell 291.5% YoY to Rs -496 million for the quarter ended September 2024, compared to a loss of Rs 127 million a year ago. Net sales declined 15.9% to Rs 26 million during the period as against Rs 31 million in July-September 2023.

For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.

The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -18.8.


Equitymaster requests your view! Post a comment on "Suven Life Sciences Gains 7%; BSE HEALTHCARE Index Up 0.2%". Click here!